RPS6 and neoplasm: Given that 2-DG is a known activator of pro-survival pathways via PI3K and insulin-like growth factor receptor 1 [14, 28], in our model, both tumor volume and burden were significantly reduced, compared with Vehicle treatment (Fig. 3), however the phosphorylation status of S6, ACC and AMPK were unchanged from Vehicle-treated mice.